Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amber Kuhl

Obstetrics & Gynecology Huntington, WV Medical Doctor

NPI 1679571905 CMS profile 166980

4270 US Route 60, Huntington, WV 25705

Open in the dashboard

General payments

$6,603

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amber Kuhl of Huntington, WV is reported in the CMS Open Payments database as having received $6,603 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $235 6
2024 General $23 1
2023 General $268 7
2022 General $131 2
2021 General $79 2
2020 General $140 8
2019 General $5,728 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amber Kuhl
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Amber Kuhl were reported at $235. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Amber Kuhl Obstetrics & Gynecology median Middle half National median
2019 $5,728 $172 $62–$391 $163
2020 $140 $94 $36–$222 $114
2021 $79 $136 $42–$369 $132
2022 $131 $160 $50–$433 $149
2023 $268 $169 $56–$423 $160
2024 $23 $152 $50–$371 $164
2025 $235 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $3,196 22 payments
  2. Medical Device Business Services, Inc. $1,844 10 payments
  3. Astellas Pharma US Inc $308 7 payments
  4. Ethicon US, LLC $301 4 payments
  5. Hologic, LLC $136 3 payments
  6. TherapeuticsMD, Inc. $124 4 payments
  7. AbbVie, Inc. $110 7 payments
  8. Merck Sharp & Dohme Corporation $96 7 payments
  9. CooperSurgical, Inc. $95 1 payment
  10. Medtronic USA, Inc. $73 1 payment
  11. Other $321 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,658 9 payments
  2. Food and Beverage $2,799 67 payments
  3. Education $146 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,196 22 payments
  2. STRATAFIX $1,925 11 payments
  3. HARMONIC Product Family $1,895 11 payments
  4. ECHELON FLEX Stapler $1,757 9 payments
  5. Surgicel Powder $262 4 payments
  6. Veozah $215 6 payments
  7. EVICEL Fibrin Sealant (Human) $164 2 payments
  8. SURGICEL Family of Absorbable Hemostats $125 1 payment
  9. NOVASURE $114 1 payment
  10. MYOSURE TISSUE REMOVAL DEVICE $114 1 payment
  11. Other $1,173 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

460

Median for Obstetrics & Gynecology: 65

Drug cost

$24,052

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

21.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 235 $14,477
Clobetasol Propionate Generic 54 $2,375
Estradiol (Twice Weekly) Estradiol Brand 23 $2,049
Dotti Estradiol Brand 14 $1,922
Progesterone Progesterone, Micronized Brand 39 $1,436
Solifenacin Succinate Generic 13 $553
Spironolactone Generic 18 $460
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 23 $420
Amitriptyline Hcl Generic 13 $213
Fluconazole Generic 15 $82

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$3,775

Medicare's payments for the services billed

Medicare patients

73

Average age 68

Services billed

80

61 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 33%
Depression 29%
Chronic kidney disease 25%
Osteoporosis 19%
Ischemic heart disease 15%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record